Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,089.00-1.77%ETH$2,256.24-1.56%GOLD$3,959.60-0.25%OIL$96.57+0.11%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACTU

Actuate Therapeutics Inc

Healthcare · Biotechnology

$0.34

Up+$0.01 (+2.06%)

Updated Nov 3, 2026, 1:53 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
86.93M
P/E ratio
-3.32
Dividend yield
0.00%
52-week range
$0.33 – $7.90
Volume
489.47K
Avg. volume
71.29K

Price performance · ACTU

ACTU price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ACTU closed at $0.34 after 20 trading sessions, down 61.70% for the selected period.

Last close
$0.34
Period change
-61.70%
Period low
$0.34
Period high
$0.87
Daily close
View OHLC price history
ACTU OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.38$0.385$0.33$0.3351489.47K
Oct 29, 2026$0.3833$0.4199$0.36$0.371814.07K
Oct 28, 2026$0.4042$0.4074$0.361$0.3833715.71K
Oct 27, 2026$0.3793$0.4378$0.35$0.39952.21M
Oct 26, 2026$0.5071$0.60$0.4751$0.5279236.32K
Oct 23, 2026$0.53$0.5563$0.4501$0.4752256.15K
Oct 22, 2026$0.57$0.5998$0.47$0.5162335K
Oct 21, 2026$0.5976$0.6379$0.5601$0.5622220.57K
Oct 20, 2026$0.5926$0.6618$0.5462$0.6161166.68K
Oct 19, 2026$0.661$0.7099$0.52$0.599727.33K
Oct 16, 2026$0.493$0.6399$0.47$0.605926.16K
Oct 15, 2026$0.457$0.55$0.4326$0.4999472.15K
Oct 14, 2026$0.48$0.49$0.41$0.4342439.47K
Oct 13, 2026$0.66$0.66$0.4383$0.4663974.4K
Oct 12, 2026$0.60$0.6801$0.60$0.6437285.88K
Oct 9, 2026$0.641$0.6799$0.6102$0.6102301.19K
Oct 8, 2026$0.6822$0.7241$0.6206$0.679324.46K
Oct 7, 2026$0.6431$0.7242$0.615$0.7242637.89K
Oct 6, 2026$0.89$0.89$0.7597$0.8116337.68K
Oct 5, 2026$0.85$0.9258$0.8007$0.8749202.23K

Latest ACTU news

The latest Smart Investors Daily articles mentioning ACTU.

Stock researchCompany · Overview

ACTU research

Overview

Company profile and research snapshot.

Company profile

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$21.00
Implied upside
—
Analysts
—
ACTU recent ratings
DateFirmRatingTarget
Aug 18, 2026HC Wainwright & Co.Buy—
Jul 30, 2026Rodman & RenshawBuy—
May 18, 2026HC Wainwright & Co.Buy—
Apr 22, 2026HC Wainwright & Co.Buy—
Apr 13, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering

CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced the pricing of an underwritten public offering of 30,985,900 shares of its common stock and warrants to purchase up to an aggregate of 15,492,950 shares of its common stock. The public offering price for each set of two shares of comm

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By